Yükleniyor... / Loading...
This study evaluates extended-release Rosiglitazone tablets as monotherapy (used alone) in people with mild-to-moderate Alzheimer's Disease. It included patients with a regular caregiver who had not taken an Alzheimer's drug in the last 30 days. It was a Phase 3 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+98
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion criteria: * Clinical diagnosis of probable Alzheimer's Disease (AD). * MMSE score 10 to 23 * Has not taken an approved AD therapy in last 30 days. * No previous hypersensitivity/intolerance to AChEIs * Have a regular caregiver. Exclusion criteria: * Diagnosis of vascular dementia. * Type I or secondary diabetes mellitus. * Type II diabetes mellitus treated with insulin, sulfonylurea or glipizide. * History or evidence of congestive heart failure, clinically significant peripheral edema or anemia. * History of significant psychiatric illness, major depressive disorder or current depression needing initiation of treatment.